Journey to Anticoagulant Access Following Payer Rejection of

Formulary restrictions can create treatment barriers for patients with atrial fibrillation, including unnecessary delays in treatment and prescription abandonment, with vulnerable populations at greater risk.

Related Keywords

United States , Louisiana , North Dakota , Greene , Minnesota , New York , California , New Orleans , Olmsted County , Lawrenceville , American , Americans , Thromb Haemost , Steven Deitelzweig , Morgan Stewart , Bristol Myers Squibb , Kevin Cramer , Coll Cardiol , Amerisourcebergen Xcenda , Health Aff Millwood , Pfizer Inc , Office Of Inspector , American Medical Association , Veterans Health Administration , International Classification Of Diseases , American College Of Physicians , Ochsner Health , Analysis Group , Steering Committee , Ethnic Disparities In Health Care , Pfizer , Optum Market Clarity Data , African American , African Americans , Clarity Data , Appendix Table , Associated With Failure , After Index Claim , Medicare Advantage , Inspector General , Improving Senior Timely Access , Care Act , International Classification , Tenth Revision , Clinical Modification , Ontario Stroke , Atrial Fibrillation , United States Medicare , Accessed June , Louisiana Medicaid , Intj Clin , Medicare Advantage Organization Denials , Medically Necessary , Senior Timely Access , Accessed August , Pract Thromb , Manag Care Spec , Med Res , Veterans Health , Ethnic Disparities , Health Care , American College , American Heart Association Task Force , Circ Cardiovasc Qual , Payer , Rejection , Anticoagulant , Apixaban ,